Exploring Three High Growth Tech Stocks in Australia

Simply Wall St · 10/15 19:09

In the last week, the Australian market has been flat, yet it is up 17% over the past year with earnings forecasted to grow by 12% annually. In this context of steady growth, identifying high-growth tech stocks involves looking for companies that demonstrate strong innovation and scalability potential in line with these positive market trends.

Top 10 High Growth Tech Companies In Australia

Name Revenue Growth Earnings Growth Growth Rating
Clinuvel Pharmaceuticals 22.32% 27.42% ★★★★★★
Pureprofile 14.94% 80.73% ★★★★★☆
Adherium 86.80% 73.66% ★★★★★★
ImExHS 20.47% 111.20% ★★★★★★
Telix Pharmaceuticals 20.19% 38.31% ★★★★★★
AVA Risk Group 32.56% 118.83% ★★★★★★
Careteq 37.17% 126.21% ★★★★★☆
Pointerra 56.62% 126.45% ★★★★★★
Wrkr 36.31% 100.29% ★★★★★★
Adveritas 57.98% 144.21% ★★★★★★

Click here to see the full list of 63 stocks from our ASX High Growth Tech and AI Stocks screener.

Let's uncover some gems from our specialized screener.

Pro Medicus (ASX:PME)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: Pro Medicus Limited is a healthcare informatics company that develops and supplies imaging software and radiology information system services to hospitals, imaging centers, and healthcare groups across Australia, North America, and Europe, with a market cap of A$19.89 billion.

Operations: Pro Medicus generates revenue primarily from producing integrated software applications for the healthcare industry, amounting to A$161.50 million. The company's offerings focus on imaging software and radiology information systems, serving clients in various regions including Australia, North America, and Europe.

Pro Medicus, a standout in the Australian tech landscape, is demonstrating robust growth with earnings projected to increase by 18.9% annually, surpassing the broader market's average of 12.2%. This growth trajectory is bolstered by a significant revenue rise of 17% per year, outpacing the Australian market's 5.5%. The company's commitment to innovation is evident from its R&D spending trends which have consistently aligned with expanding its technological capabilities in healthcare imaging solutions. Recent financial outcomes underscore this momentum; for FY2024, Pro Medicus reported a revenue surge to AUD 166.33 million from AUD 127.33 million in the previous year and an impressive jump in net income to AUD 82.79 million up from AUD 60.65 million. Moreover, Pro Medicus has enhanced shareholder returns through strategic capital management evidenced by a recent dividend hike to 40 cents fully franked—an increase of over one-third compared to last year—reflecting confidence in sustained profitability and cash flow positivity. These financial maneuvers not only highlight their fiscal prudence but also reinforce their stature within high-growth sectors driven by advanced software solutions and client-centric innovations.

ASX:PME Revenue and Expenses Breakdown as at Oct 2024
ASX:PME Revenue and Expenses Breakdown as at Oct 2024

REA Group (ASX:REA)

Simply Wall St Growth Rating: ★★★★☆☆

Overview: REA Group Limited operates an online property advertising business across Australia, India, the United States, Malaysia, Singapore, Thailand, Vietnam, and internationally with a market capitalization of A$29.59 billion.

Operations: The company generates revenue primarily from its property and online advertising segment in Australia, which contributes A$1.25 billion, followed by financial services in Australia at A$320.60 million and operations in India with A$103.10 million. The focus on these key regions highlights a diversified approach to capturing market opportunities across different geographies.

REA Group, navigating through a challenging year with a 15% dip in earnings, still forecasts robust revenue growth at 6.5% annually, outpacing the Australian market's average of 5.5%. This resilience is underscored by an anticipated surge in earnings growth at 16.8% per year. The company's commitment to innovation and development is evident from its significant R&D expenditure, which aligns closely with its strategic goals to enhance interactive media and services capabilities. Despite recent financial setbacks marked by a one-off loss of AUD 153.6 million, REA Group has demonstrated fiscal prudence through a dividend increase to AUD 1.02 per share fully franked, reflecting confidence in future cash flow and profitability prospects within the competitive tech landscape of Australia.

ASX:REA Earnings and Revenue Growth as at Oct 2024
ASX:REA Earnings and Revenue Growth as at Oct 2024

Xero (ASX:XRO)

Simply Wall St Growth Rating: ★★★★★☆

Overview: Xero Limited is a software as a service company that offers online business solutions for small businesses and their advisors in Australia, New Zealand, and internationally, with a market cap of A$22.88 billion.

Operations: Xero generates revenue by providing online solutions for small businesses and their advisors, with reported revenue of NZ$1.71 billion. The company's business model focuses on delivering software as a service to its target markets across Australia, New Zealand, and internationally.

Xero, amid leadership transitions and innovative product launches, is setting a brisk pace in the tech sector with its new inventory management solutions aimed at enhancing small business operations in the U.S. With expected revenue growth of 14% per year outstripping the Australian market forecast of 5.5%, Xero demonstrates robust potential in revenue generation. Furthermore, its commitment to R&D is underscored by an impressive forecasted annual earnings growth rate of 24.6%. This focus on innovation and market expansion is exemplified by recent integrations with major platforms like Amazon's FBA and Caseware, positioning Xero favorably for sustained competitive advantage in both local and international markets.

ASX:XRO Revenue and Expenses Breakdown as at Oct 2024
ASX:XRO Revenue and Expenses Breakdown as at Oct 2024

Next Steps

Looking For Alternative Opportunities?

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.